Compare Duke Energy Corp (DUK) vs 10X Genomics Inc (TXG) Price & Performance

Duke Energy (DUK) trades at $126.86, up 1.1% on the day, with a bullish technical outlook and consistent earnings beats in recent quarters. The stock shows stable revenue growth, with 2025 revenue reaching $32.24B and net income of $4.97B, supported by a 15.49% net margin. Recent news highlights a dividend increase to $1.085 per share and strong institutional interest, with 37.5% of analysts rating it a Buy.

The outlook remains positive with a consensus price target of $136.60, offering ~7.7% upside. Risks include high debt levels (46.17% debt-to-asset ratio) and regulatory pressures, but the company's defensive utility profile and dividend reliability provide stability amid market volatility.

TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.

The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.